Reported about 11 hours ago
Vertex Pharmaceuticals experienced a significant 12% drop in its stock price following disappointing first-quarter results, including a revenue miss and a clinical setback for a cystic fibrosis treatment. However, historical data suggests that the company usually rebounds from such declines, indicating this could be a buying opportunity. Despite recent challenges, Vertex's strong portfolio and promising pipeline keep its long-term outlook favorable.
Source: YAHOO